Drug Profile
Research programme: apoptosis stimulants - TetraLogic Pharmaceuticals
Alternative Names: GT 12726; GT 12794; GT 12810; GT 12869; GT 12882; GT 12911Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Princeton University
- Developer TetraLogic Pharmaceuticals
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Inhibitor of apoptosis protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 16 Jan 2014 Preclinical development is ongoing in USA
- 19 Nov 2009 Preclinical pharmacodynamics, pharmacokinetics and safety data presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)